Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth
of cancer cells by stopping blood flow to the tumor. It is not yet known whether bevacizumab
works better with or without thalidomide for multiple myeloma.
PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without
thalidomide in treating patients who have relapsed or refractory multiple myeloma.